FDA批准脐带血制品

2011-11-28 MedSci原创 MedSci原创

  11月10日,美国FDA批准第一个特许脐带造血祖细胞(HPC-C)——HEMACORD细胞疗法。HEMACORD适用于有造血系统疾病患者的造血干细胞移植。例如,脐带血移植已用于治疗某些血癌、某些遗传代谢和免疫系统疾病。   HEMACORD含有来自人脐带血的造血祖细胞(HPCs)。脐带血是用于移植HPCs的3个来源之一,其他2个来源是骨髓和外周血。一旦这些 HPCs被输入病人体内,移行至骨髓

  11月10日,美国FDA批准第一个特许脐带造血祖细胞(HPC-C)——HEMACORD细胞疗法。HEMACORD适用于有造血系统疾病患者的造血干细胞移植。例如,脐带血移植已用于治疗某些血癌、某些遗传代谢和免疫系统疾病。

  HEMACORD含有来自人脐带血的造血祖细胞(HPCs)。脐带血是用于移植HPCs的3个来源之一,其他2个来源是骨髓和外周血。一旦这些 HPCs被输入病人体内,移行至骨髓,在骨髓中分裂和发育成熟。当这些成熟细胞进入血流就能部分地或完全地恢复多种血细胞的数量和功能,包括免疫功能。

  FDA告诫,HEMACORD的加框警告涉及有关发生移植物抗宿主病(GVHD)、移植物移入综合征、移植物失功和输注反应的危险,上述每种危险都可能是致命的。对接受HEMACORD的病人应小心监测。有关HEMACORD的风险获益评估、单位选择和给药,应听从有造血干细胞移植经验的医师指导。

  英文链接:FDA approves first cord blood product

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2009820, encodeId=dfe32009820f6, content=<a href='/topic/show?id=48e58892623' target=_blank style='color:#2F92EE;'>#血制品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88926, encryptionId=48e58892623, topicName=血制品)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sun May 13 18:35:00 CST 2012, time=2012-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839128, encodeId=4db7183912817, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Thu Mar 15 02:35:00 CST 2012, time=2012-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355129, encodeId=69d4135512932, content=<a href='/topic/show?id=3b47846692b' target=_blank style='color:#2F92EE;'>#脐带血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84669, encryptionId=3b47846692b, topicName=脐带血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 30 13:35:00 CST 2011, time=2011-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542355, encodeId=ba6115423553a, content=<a href='/topic/show?id=82c0846654a' target=_blank style='color:#2F92EE;'>#脐带#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84665, encryptionId=82c0846654a, topicName=脐带)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06713409761, createdName=1249859em42(暂无昵称), createdTime=Wed Nov 30 13:35:00 CST 2011, time=2011-11-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2009820, encodeId=dfe32009820f6, content=<a href='/topic/show?id=48e58892623' target=_blank style='color:#2F92EE;'>#血制品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88926, encryptionId=48e58892623, topicName=血制品)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sun May 13 18:35:00 CST 2012, time=2012-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839128, encodeId=4db7183912817, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Thu Mar 15 02:35:00 CST 2012, time=2012-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355129, encodeId=69d4135512932, content=<a href='/topic/show?id=3b47846692b' target=_blank style='color:#2F92EE;'>#脐带血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84669, encryptionId=3b47846692b, topicName=脐带血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 30 13:35:00 CST 2011, time=2011-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542355, encodeId=ba6115423553a, content=<a href='/topic/show?id=82c0846654a' target=_blank style='color:#2F92EE;'>#脐带#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84665, encryptionId=82c0846654a, topicName=脐带)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06713409761, createdName=1249859em42(暂无昵称), createdTime=Wed Nov 30 13:35:00 CST 2011, time=2011-11-30, status=1, ipAttribution=)]
    2012-03-15 bugit
  3. [GetPortalCommentsPageByObjectIdResponse(id=2009820, encodeId=dfe32009820f6, content=<a href='/topic/show?id=48e58892623' target=_blank style='color:#2F92EE;'>#血制品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88926, encryptionId=48e58892623, topicName=血制品)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sun May 13 18:35:00 CST 2012, time=2012-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839128, encodeId=4db7183912817, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Thu Mar 15 02:35:00 CST 2012, time=2012-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355129, encodeId=69d4135512932, content=<a href='/topic/show?id=3b47846692b' target=_blank style='color:#2F92EE;'>#脐带血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84669, encryptionId=3b47846692b, topicName=脐带血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 30 13:35:00 CST 2011, time=2011-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542355, encodeId=ba6115423553a, content=<a href='/topic/show?id=82c0846654a' target=_blank style='color:#2F92EE;'>#脐带#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84665, encryptionId=82c0846654a, topicName=脐带)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06713409761, createdName=1249859em42(暂无昵称), createdTime=Wed Nov 30 13:35:00 CST 2011, time=2011-11-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2009820, encodeId=dfe32009820f6, content=<a href='/topic/show?id=48e58892623' target=_blank style='color:#2F92EE;'>#血制品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88926, encryptionId=48e58892623, topicName=血制品)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sun May 13 18:35:00 CST 2012, time=2012-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839128, encodeId=4db7183912817, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Thu Mar 15 02:35:00 CST 2012, time=2012-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355129, encodeId=69d4135512932, content=<a href='/topic/show?id=3b47846692b' target=_blank style='color:#2F92EE;'>#脐带血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84669, encryptionId=3b47846692b, topicName=脐带血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 30 13:35:00 CST 2011, time=2011-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542355, encodeId=ba6115423553a, content=<a href='/topic/show?id=82c0846654a' target=_blank style='color:#2F92EE;'>#脐带#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84665, encryptionId=82c0846654a, topicName=脐带)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06713409761, createdName=1249859em42(暂无昵称), createdTime=Wed Nov 30 13:35:00 CST 2011, time=2011-11-30, status=1, ipAttribution=)]

相关资讯

FDA开始监管和测量移动医疗软件

美国食品药品管理局(FDA)首次对在手机和其他手持智能移动设备中迅速扩大应用的医疗APP软件进行监管和测量。   App软件是苹果公司为iPhone、iPod Touch以及iPad等开发的应用程序。近两年,为这些智能移动设备而设计的医疗应用功能迅速增多,据西方分析师估计,已经超过1.7万项,范围覆盖了体温计至医疗扫描等各种门类。   然而,这些手持智能移动设备的医疗应用能不能正常工

FDA批准阿柏西普治疗老年黄斑变性

  11月18日,美国食品与药物管理局(FDA)批准Eylea(阿柏西普,aflibercept) 治疗有新生血管的年龄相关性黄斑变性(AMD),该病是美国60岁以上人群视力丧失和致盲的首要原因。   两项纳入2412例成年患者的临床试验评价了Eylea的安全性和有效性。参试者接受Eylea或Lucentis(雷珠单抗注射)治疗。两研究的主要终点是治疗一年后病人视力的视敏度。   每

FDA批准治疗骨髓纤维化药ruxolitinib上市

    11月16日,美国食品与药物管理局(FDA)批准Jakafi(ruxolitinib)上市,这是第一个获准的专门治疗骨髓纤维化的药物。   骨髓纤维化是骨髓被瘢痕组织替换,导致血细胞在肝脏和脾脏生成,该病的特征是脾肿大、贫血、白细胞和血小板减少,以及骨髓纤维化的相关症状,包括乏力、腹部不适、肋骨下疼痛、肌肉骨骼疼痛、瘙痒和盗汗。   Jakafi(每次1片,每日2次)抑制J

FDA:2011财政年度批准的创新性新药

报告显示,美国在快速批准药物安全性及有效性方面位于世界领先水平。 在过去的一年中,美国食品药物管理局批准了35个新药,是在过去十年内仅次于2009年(37个)的批准数量。 报告显示美国快速批准安全和有效药物走在其它各国之前。 美国食品药品监督管理局在过去的12个月内批准了35个新药。这是在过去十年内批准的最高数目,仅低于2009年(37个)。许多药物都对患者的治疗有重要进展,包括两个丙肝

FDA批准氯巴占(clobazam)治疗重型癫痫

  10月24日,美国食品和药物管理局(FDA)批准Onfi(通用名:氯巴占 clobazam)用于成人和≥2岁儿童,作为Lennox-Gastaut综合征相关癫痫的辅助治疗。   美国FDA药物评价与研究中心神经病产品部主任罗素(Russell Katz)说:“Lennox-Gastaut综合征是癫痫的严重类型,可引起致残性惊厥发作。这种疾病治疗困难,这种药使该病有了更多的

2011年第三季度FDA批准的部分新药

2011年第三季度以来,美国食品与药物管理局(FDA)批准的新产品涵盖了肿瘤科、心血管科、疫苗研发以及罕见病治疗等诸多领域。  与前两个季度不同的是,除了新批准的治疗性药物,还包括了与其配套的诊断性试验,如批准了Xalkori (crizotinib)治疗某些有局部晚期或转移性非小细胞肺癌患者,与其配套的诊断性试验Vysis ALK分离FISH探针检测盒一同获准,有助于确定病人